Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions
[Display omitted] The effects of tablet preparation and subsequent film coating with amorphous solid dispersion (ASD) particles that were composed of a drug with poor water solubility and hydrophilic polymers were investigated. ASD particles were prepared with a drug and vinylpyrrolidone–vinyl aceta...
Saved in:
Published in | International journal of pharmaceutics Vol. 540; no. 1-2; pp. 171 - 177 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
05.04.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | [Display omitted]
The effects of tablet preparation and subsequent film coating with amorphous solid dispersion (ASD) particles that were composed of a drug with poor water solubility and hydrophilic polymers were investigated. ASD particles were prepared with a drug and vinylpyrrolidone–vinyl acetate copolymer (PVPVA) or polyvinylpyrrolidone (PVP) at a weight ratio of 1:1 or 1:2 using a melt extrusion technique. Tablets were prepared by conventional direct compression followed by pan coating. A mathematical model based on the Noyes–Whitney equation assuming that stable crystals precipitated at the changeable surface area of the solid–liquid interface used to estimate drug dissolution kinetics in a non-sink dissolution condition. All the ASD particles showed a maximum dissolution concentration approximately ten times higher than that of the crystalline drug. The ASD particles with PVPVA showed higher precipitation rate with lower polymer ratio, while PVP did not precipitate within 960 min regardless of the polymer ratio, suggesting the ASD particles of 1:1 drug:PVPVA (ASD-1) were the most unstable among the ASD particles considered. The dissolution of a core tablet with ASD-1 showed less supersaturation and a much higher precipitation rate than those of ASD-1 particles. However, a film-coated tablet or core tablet with a trace amount of hydroxypropylmethylcellulose (HPMC) showed a similar dissolution profile to that of the ASD-1 particles, indicating HPMC had a remarkable precipitation inhibition effect. Overall, these results suggest that tablet preparation with ASD may adversely affect the maintenance of supersaturation; however, this effect can be mitigated by adding an appropriate precipitation inhibitor to the formulation. |
---|---|
AbstractList | The effects of tablet preparation and subsequent film coating with amorphous solid dispersion (ASD) particles that were composed of a drug with poor water solubility and hydrophilic polymers were investigated. ASD particles were prepared with a drug and vinylpyrrolidone-vinyl acetate copolymer (PVPVA) or polyvinylpyrrolidone (PVP) at a weight ratio of 1:1 or 1:2 using a melt extrusion technique. Tablets were prepared by conventional direct compression followed by pan coating. A mathematical model based on the Noyes-Whitney equation assuming that stable crystals precipitated at the changeable surface area of the solid-liquid interface used to estimate drug dissolution kinetics in a non-sink dissolution condition. All the ASD particles showed a maximum dissolution concentration approximately ten times higher than that of the crystalline drug. The ASD particles with PVPVA showed higher precipitation rate with lower polymer ratio, while PVP did not precipitate within 960 min regardless of the polymer ratio, suggesting the ASD particles of 1:1 drug:PVPVA (ASD-1) were the most unstable among the ASD particles considered. The dissolution of a core tablet with ASD-1 showed less supersaturation and a much higher precipitation rate than those of ASD-1 particles. However, a film-coated tablet or core tablet with a trace amount of hydroxypropylmethylcellulose (HPMC) showed a similar dissolution profile to that of the ASD-1 particles, indicating HPMC had a remarkable precipitation inhibition effect. Overall, these results suggest that tablet preparation with ASD may adversely affect the maintenance of supersaturation; however, this effect can be mitigated by adding an appropriate precipitation inhibitor to the formulation. [Display omitted] The effects of tablet preparation and subsequent film coating with amorphous solid dispersion (ASD) particles that were composed of a drug with poor water solubility and hydrophilic polymers were investigated. ASD particles were prepared with a drug and vinylpyrrolidone–vinyl acetate copolymer (PVPVA) or polyvinylpyrrolidone (PVP) at a weight ratio of 1:1 or 1:2 using a melt extrusion technique. Tablets were prepared by conventional direct compression followed by pan coating. A mathematical model based on the Noyes–Whitney equation assuming that stable crystals precipitated at the changeable surface area of the solid–liquid interface used to estimate drug dissolution kinetics in a non-sink dissolution condition. All the ASD particles showed a maximum dissolution concentration approximately ten times higher than that of the crystalline drug. The ASD particles with PVPVA showed higher precipitation rate with lower polymer ratio, while PVP did not precipitate within 960 min regardless of the polymer ratio, suggesting the ASD particles of 1:1 drug:PVPVA (ASD-1) were the most unstable among the ASD particles considered. The dissolution of a core tablet with ASD-1 showed less supersaturation and a much higher precipitation rate than those of ASD-1 particles. However, a film-coated tablet or core tablet with a trace amount of hydroxypropylmethylcellulose (HPMC) showed a similar dissolution profile to that of the ASD-1 particles, indicating HPMC had a remarkable precipitation inhibition effect. Overall, these results suggest that tablet preparation with ASD may adversely affect the maintenance of supersaturation; however, this effect can be mitigated by adding an appropriate precipitation inhibitor to the formulation. |
Author | Iwao, Yasunori Kimura, Shin-ichiro Sakai, Toshiro Itai, Shigeru Hirai, Daiki |
Author_xml | – sequence: 1 givenname: Toshiro surname: Sakai fullname: Sakai, Toshiro organization: Pharmaceutical Research and Technology Labs. US, Astellas US Technology Inc., 1 Astellas Way, Northbrook, 60062 Illinois, United States – sequence: 2 givenname: Daiki surname: Hirai fullname: Hirai, Daiki organization: Department of Pharmaceutical Engineering, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan – sequence: 3 givenname: Shin-ichiro surname: Kimura fullname: Kimura, Shin-ichiro organization: Department of Pharmaceutical Engineering, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan – sequence: 4 givenname: Yasunori surname: Iwao fullname: Iwao, Yasunori organization: Department of Pharmaceutical Engineering, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan – sequence: 5 givenname: Shigeru orcidid: 0000-0003-4035-3591 surname: Itai fullname: Itai, Shigeru email: s-itai@u-shizuoka-ken.ac.jp organization: Department of Pharmaceutical Engineering, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29447848$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU9v1DAQxS1URLd_PgLIRy4bxnESZ08IVaUgVeICZ8uxx6xXSRxspxJnvjiz3S1XTj6892b8fnPFLuY4I2NvBVQCRPfhUIXDsjdpqmoQfQV1BUK-YhvRK7mVjeou2Aak6retUPKSXeV8AICuFvINu6x3TaP6pt-wP_feoy2ZR8-LGUYs3Mc0raMpIc7czI7ndcj4a8WZpDBO3EbS5p-c5LJHkhdM2ZQ1mYKOu5BzHNfn9IB78xRiOg43U0zLPq6Zkxyefccc2fINe-3NmPH2_F6zH5_vv9992T5-e_h69-lxa2XXFioC0hsnnOmph9zBzrUopG0aITvsdnVjBxDgGwWDrxVap8CKDltlZCs7I6_Z-9PcJUXqk4ueQrY4jmZG-piuASQho2VkbU9Wm2LOCb1eUphM-q0F6CN_fdBn_vrIX0OtiT_l3p1XrMOE7l_qBTgZPp4MSEWfAiadbcDZoguJ7qBdDP9Z8RfkK55F |
CitedBy_id | crossref_primary_10_1016_j_ejps_2020_105682 crossref_primary_10_1016_j_ijpharm_2020_119504 crossref_primary_10_1007_s40005_023_00652_9 crossref_primary_10_1016_j_ijpharm_2022_122524 crossref_primary_10_1208_s12249_021_01986_z crossref_primary_10_1016_j_ijpharm_2018_08_012 crossref_primary_10_1016_j_ijpharm_2019_01_009 crossref_primary_10_1208_s12249_020_01909_4 crossref_primary_10_1016_j_ijpharm_2022_122110 crossref_primary_10_1080_03639045_2018_1562467 crossref_primary_10_1016_j_ejps_2019_02_005 crossref_primary_10_1016_j_ijbiomac_2023_124825 crossref_primary_10_1016_j_lwt_2020_109556 crossref_primary_10_1016_j_ijpharm_2022_121881 crossref_primary_10_3390_pharmaceutics13071034 crossref_primary_10_3390_pharmaceutics13050731 crossref_primary_10_1016_j_ijpx_2024_100259 |
Cites_doi | 10.1016/S0169-409X(96)00423-1 10.1016/j.ijpharm.2013.05.013 10.1016/j.ijpharm.2017.02.050 10.1002/jps.20906 10.1002/jps.21903 10.1016/j.ijpharm.2011.05.055 10.1016/S0939-6411(02)00061-9 10.1016/j.powtec.2015.08.047 10.1016/j.ijpharm.2003.07.010 10.1021/mp1003493 10.1016/j.ijpharm.2005.05.017 10.1021/mp500711c 10.1016/S0939-6411(00)00076-X 10.1016/j.ejpb.2013.09.007 10.1208/pt070368 10.1248/cpb.60.459 10.1021/js980403l 10.1016/S1056-8719(00)00107-6 10.1016/S0378-5173(97)00274-3 10.1016/j.ddtec.2011.10.002 10.1016/j.ejpb.2016.09.011 10.1248/cpb.52.244 10.1021/mp500480y 10.1016/j.ijpharm.2013.01.067 10.3109/10837450.2010.535826 10.1016/j.ijpharm.2011.08.032 |
ContentType | Journal Article |
Copyright | 2018 Elsevier B.V. Copyright © 2018 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2018 Elsevier B.V. – notice: Copyright © 2018 Elsevier B.V. All rights reserved. |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.ijpharm.2018.02.013 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-3476 |
EndPage | 177 |
ExternalDocumentID | 10_1016_j_ijpharm_2018_02_013 29447848 S0378517318300942 |
Genre | Journal Article |
GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 5GY 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AATCM AAXUO ABFNM ABFRF ABJNI ABMAC ABOCM ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KOM M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SCC SDF SDG SDP SES SPCBC SSP SSZ T5K TEORI ~02 ~G- AAQFI AAXKI AKRWK NPM .GJ 29J 3O- 53G 5VS AAQXK AAYXX ABXDB ADMUD AFJKZ ASPBG AVWKF AZFZN CITATION FEDTE FGOYB G-2 HMT HVGLF HZ~ R2- SEW SPT WUQ ZXP 7X8 |
ID | FETCH-LOGICAL-c365t-5103fad1da80623909d5e13c44136e6924cb010f470bf27ecd70c16e57a3536a3 |
IEDL.DBID | .~1 |
ISSN | 0378-5173 |
IngestDate | Sun Sep 29 07:15:43 EDT 2024 Thu Sep 26 16:34:40 EDT 2024 Wed Oct 16 00:59:21 EDT 2024 Fri Feb 23 02:29:54 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1-2 |
Keywords | Amorphous solid dispersion Solid–liquid interface Polyvinylpyrrolidone Dissolution model Copovidone Melt extrusion |
Language | English |
License | Copyright © 2018 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c365t-5103fad1da80623909d5e13c44136e6924cb010f470bf27ecd70c16e57a3536a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-4035-3591 |
PMID | 29447848 |
PQID | 2003037365 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_2003037365 crossref_primary_10_1016_j_ijpharm_2018_02_013 pubmed_primary_29447848 elsevier_sciencedirect_doi_10_1016_j_ijpharm_2018_02_013 |
PublicationCentury | 2000 |
PublicationDate | 2018-04-05 |
PublicationDateYYYYMMDD | 2018-04-05 |
PublicationDate_xml | – month: 04 year: 2018 text: 2018-04-05 day: 05 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | International journal of pharmaceutics |
PublicationTitleAlternate | Int J Pharm |
PublicationYear | 2018 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Jahangiri, Barzegar-jalali, Garjani, Javadzadeh, Hamishehkar (b9000) 2015; 286 Ku, Dulin (b0060) 2012; 17 Serajuddln (b0105) 1999; 88 Wlodarski, Tajber, Sawicki (b0135) 2016; 109 Sun, Lee (b0110) 2015; 12 Teja, Patil, Shete, Patel, Bansal (b0115) 2013; 4 Chaulang, Patil, Ghodke, Khan, Yeole (b0015) 2008; 1 Van Den Mooter (b0125) 2012; 9 Kawabata, Wada, Nakatani, Yamada, Onoue (b0045) 2011; 420 Won, Kim, Lee, Park, Hwang (b0140) 2005; 301 Okimoto, Miyake, Ibuki, Yasumura (b0095) 1997; 159 Lipinski, Franc, Feeney (b0070) 1997; 23 Leuner, Dressman (b0065) 2000; 50 Lipinski (b0080) 2000; 44 Yamashita, Nakate, Okimoto, Ohike (b0150) 2003; 267 Hirasawa, Ishise, Miyata, Danjo (b0040) 2004; 52 Murdande, Pikal, Shanker, Bogner (b0090) 2010; 99 Modi, Tayade (b0085) 2006; 7 Han, Lee, Lee (b0030) 2011; 415 Vo, Park, Lee (b0130) 2013; 85 Guzman, Tawa, Zhang, Ratanabanangkoon, Shaw, Gardner, Chen, Moreau, Almarsson, Remenar (b0025) 2007; 96 Thommes, Ely, Carvajal, Pinal (b0120) 2011 Gardner, Walsh, Almarsson (b0020) 2004; 3 Sakurai, Sakai, Sako, Maitani (b0100) 2012; 60 Keen, Hughey, Bennett, Jannin, Rosiaux, Marchaud, Mcginity (b0050) 2015; 12 Kim, Kim, Cho, Cha, Park, Park, Hwang (b0055) 2013; 445 Hirai, Iwao, Kimura, Noguchi, Itai (b0035) 2017; 522 Lipinski (b0075) 2002; 5 Arunprasad, Narayanan, Rajalakshmi (b0005) 2010; 3 Breitenbach (b0010) 2002; 54 Xu, Dai (b0145) 2013; 453 Van Den Mooter (10.1016/j.ijpharm.2018.02.013_b0125) 2012; 9 Vo (10.1016/j.ijpharm.2018.02.013_b0130) 2013; 85 Chaulang (10.1016/j.ijpharm.2018.02.013_b0015) 2008; 1 Okimoto (10.1016/j.ijpharm.2018.02.013_b0095) 1997; 159 Lipinski (10.1016/j.ijpharm.2018.02.013_b0075) 2002; 5 Guzman (10.1016/j.ijpharm.2018.02.013_b0025) 2007; 96 Yamashita (10.1016/j.ijpharm.2018.02.013_b0150) 2003; 267 Sakurai (10.1016/j.ijpharm.2018.02.013_b0100) 2012; 60 Wlodarski (10.1016/j.ijpharm.2018.02.013_b0135) 2016; 109 Kawabata (10.1016/j.ijpharm.2018.02.013_b0045) 2011; 420 Teja (10.1016/j.ijpharm.2018.02.013_b0115) 2013; 4 Breitenbach (10.1016/j.ijpharm.2018.02.013_b0010) 2002; 54 Arunprasad (10.1016/j.ijpharm.2018.02.013_b0005) 2010; 3 Jahangiri (10.1016/j.ijpharm.2018.02.013_b9000) 2015; 286 Won (10.1016/j.ijpharm.2018.02.013_b0140) 2005; 301 Lipinski (10.1016/j.ijpharm.2018.02.013_b0070) 1997; 23 Xu (10.1016/j.ijpharm.2018.02.013_b0145) 2013; 453 Modi (10.1016/j.ijpharm.2018.02.013_b0085) 2006; 7 Hirasawa (10.1016/j.ijpharm.2018.02.013_b0040) 2004; 52 Keen (10.1016/j.ijpharm.2018.02.013_b0050) 2015; 12 Hirai (10.1016/j.ijpharm.2018.02.013_b0035) 2017; 522 Murdande (10.1016/j.ijpharm.2018.02.013_b0090) 2010; 99 Thommes (10.1016/j.ijpharm.2018.02.013_b0120) 2011 Serajuddln (10.1016/j.ijpharm.2018.02.013_b0105) 1999; 88 Han (10.1016/j.ijpharm.2018.02.013_b0030) 2011; 415 Leuner (10.1016/j.ijpharm.2018.02.013_b0065) 2000; 50 Lipinski (10.1016/j.ijpharm.2018.02.013_b0080) 2000; 44 Kim (10.1016/j.ijpharm.2018.02.013_b0055) 2013; 445 Ku (10.1016/j.ijpharm.2018.02.013_b0060) 2012; 17 Sun (10.1016/j.ijpharm.2018.02.013_b0110) 2015; 12 Gardner (10.1016/j.ijpharm.2018.02.013_b0020) 2004; 3 |
References_xml | – volume: 415 start-page: 89 year: 2011 end-page: 94 ident: b0030 article-title: Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation publication-title: Int. J. Pharm. contributor: fullname: Lee – volume: 301 start-page: 199 year: 2005 end-page: 208 ident: b0140 article-title: Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process publication-title: Int. J. Pharm. contributor: fullname: Hwang – volume: 17 start-page: 285 year: 2012 end-page: 302 ident: b0060 article-title: A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept publication-title: Pharm. Dev. Technol. contributor: fullname: Dulin – volume: 85 start-page: 799 year: 2013 end-page: 813 ident: b0130 article-title: Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs publication-title: Eur. J. Pharm. Biopharm. contributor: fullname: Lee – volume: 23 start-page: 3 year: 1997 end-page: 25 ident: b0070 article-title: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings publication-title: Adv. Drug Deliv. Rev. contributor: fullname: Feeney – volume: 99 start-page: 1254 year: 2010 end-page: 1264 ident: b0090 article-title: Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis publication-title: J. Pharm. Sci. contributor: fullname: Bogner – volume: 54 start-page: 107 year: 2002 end-page: 117 ident: b0010 article-title: Melt extrusion: from process to drug delivery technology publication-title: Eur. J. Pharm. Biopharm. contributor: fullname: Breitenbach – volume: 445 start-page: 108 year: 2013 end-page: 116 ident: b0055 article-title: Supersaturatable formulations for the enhanced oral absorption of sirolimus publication-title: Int. J. Pharm. contributor: fullname: Hwang – start-page: 727 year: 2011 end-page: 735 ident: b0120 article-title: Improvement of the dissolution rate of poorly soluble drugs by solid crystal suspensions publication-title: Mol. Pharm. contributor: fullname: Pinal – volume: 109 start-page: 14 year: 2016 end-page: 23 ident: b0135 article-title: Physicochemical properties of direct compression tablets with spray dried and ball milled solid dispersions of tadalafil in PVP-VA publication-title: Eur. J. Pharm. Biopharm. contributor: fullname: Sawicki – volume: 522 start-page: 58 year: 2017 end-page: 65 ident: b0035 article-title: Mathematical model to analyze the dissolution behavior of metastable crystals or amorphous drug accompanied with a solid-liquid interface reaction publication-title: Int. J. Pharm. contributor: fullname: Itai – volume: 88 start-page: 1058 year: 1999 end-page: 1066 ident: b0105 article-title: Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs publication-title: J. Pharm. Sci. contributor: fullname: Serajuddln – volume: 286 start-page: 538 year: 2015 end-page: 545 ident: b9000 article-title: Pharmacological and histological examination of atorvastatin-PVP K30 solid dispersions publication-title: Powder Technol. contributor: fullname: Hamishehkar – volume: 420 start-page: 1 year: 2011 end-page: 10 ident: b0045 article-title: Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system : Basic approaches and practical applications publication-title: Int. J. Pharm. contributor: fullname: Onoue – volume: 4 start-page: 70 year: 2013 end-page: 94 ident: b0115 article-title: Drug-excipient behavior in polymeric amorphous solid dispersions publication-title: J. Excipients Food Chem. contributor: fullname: Bansal – volume: 52 start-page: 244 year: 2004 end-page: 247 ident: b0040 article-title: Application of nilvadipine solid dispersion to tablet formulation and manufacturing using crospovidone and methylcellulose as dispersion carriers publication-title: Chem. Pharm. Bull. contributor: fullname: Danjo – volume: 1 start-page: 386 year: 2008 end-page: 389 ident: b0015 article-title: Preparation and characterization of solid dispersion tablet of furosemide with crospovidone publication-title: J. Pharm. Tech. contributor: fullname: Yeole – volume: 12 start-page: 120 year: 2015 end-page: 126 ident: b0050 article-title: Eff ect of tablet structure on controlled release from supersaturating solid dispersions containing glyceryl behenate publication-title: Mol. Pharm. contributor: fullname: Mcginity – volume: 453 start-page: 36 year: 2013 end-page: 43 ident: b0145 article-title: Drug precipitation inhibitors in supersaturable formulations publication-title: Int. J. Pharm. contributor: fullname: Dai – volume: 7 start-page: 1 year: 2006 end-page: 6 ident: b0085 article-title: Enhancement of dissolution profile by solid dispersion (kneading) technique publication-title: AAPS PharmSciTech contributor: fullname: Tayade – volume: 60 start-page: 459 year: 2012 end-page: 464 ident: b0100 article-title: Polymer combination increased both physical stability and oral absorption of solid dispersions containing a low glass transition temperature drug : physicochemical characterization and in vivo study publication-title: Chem. Pharm. Bull. contributor: fullname: Maitani – volume: 3 start-page: 130 year: 2010 end-page: 134 ident: b0005 article-title: Preparation and evaluation of solid dispersion of terbinafine hydrochloride publication-title: Int. J. Pharm. Sci. Rev. Res. contributor: fullname: Rajalakshmi – volume: 159 start-page: 85 year: 1997 end-page: 93 ident: b0095 article-title: Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose publication-title: Int. J. Pharm. contributor: fullname: Yasumura – volume: 44 start-page: 235 year: 2000 end-page: 249 ident: b0080 article-title: Drug-like properties and the causes of poor solubility and poor permeability publication-title: J. Pharamacol. Toxicol. Methods contributor: fullname: Lipinski – volume: 96 start-page: 2686 year: 2007 end-page: 2702 ident: b0025 article-title: Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations publication-title: J. Pharm. Sci. contributor: fullname: Remenar – volume: 3 start-page: 926 year: 2004 end-page: 934 ident: b0020 article-title: Drugs as materials: valuing physical form in drug discovery publication-title: Nat. Rev. contributor: fullname: Almarsson – volume: 12 start-page: 1203 year: 2015 end-page: 1215 ident: b0110 article-title: Evolution of supersaturation of amorphous pharmaceuticals: Nonlinear rate of supersaturation generation regulated by matrix diffusion publication-title: Mol. Pharm. contributor: fullname: Lee – volume: 5 start-page: 82 year: 2002 end-page: 85 ident: b0075 article-title: Poor aqueous solubility – an industry wide problem in drug discovery publication-title: Am. Pharm. Rev. contributor: fullname: Lipinski – volume: 9 start-page: e79 year: 2012 end-page: e85 ident: b0125 article-title: The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate publication-title: Drug Discov. Today Technol. contributor: fullname: Van Den Mooter – volume: 50 start-page: 47 year: 2000 end-page: 60 ident: b0065 article-title: Improving drug solubility for oral delivery using solid dispersions publication-title: Eur. J. Pharm. Biopharm. contributor: fullname: Dressman – volume: 267 start-page: 79 year: 2003 end-page: 91 ident: b0150 article-title: Establishment of new preparation method for solid dispersion formulation of tacrolimus publication-title: Int. J. Pharm. contributor: fullname: Ohike – volume: 23 start-page: 3 year: 1997 ident: 10.1016/j.ijpharm.2018.02.013_b0070 article-title: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/S0169-409X(96)00423-1 contributor: fullname: Lipinski – volume: 4 start-page: 70 year: 2013 ident: 10.1016/j.ijpharm.2018.02.013_b0115 article-title: Drug-excipient behavior in polymeric amorphous solid dispersions publication-title: J. Excipients Food Chem. contributor: fullname: Teja – volume: 453 start-page: 36 year: 2013 ident: 10.1016/j.ijpharm.2018.02.013_b0145 article-title: Drug precipitation inhibitors in supersaturable formulations publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2013.05.013 contributor: fullname: Xu – volume: 522 start-page: 58 year: 2017 ident: 10.1016/j.ijpharm.2018.02.013_b0035 article-title: Mathematical model to analyze the dissolution behavior of metastable crystals or amorphous drug accompanied with a solid-liquid interface reaction publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2017.02.050 contributor: fullname: Hirai – volume: 96 start-page: 2686 year: 2007 ident: 10.1016/j.ijpharm.2018.02.013_b0025 article-title: Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations publication-title: J. Pharm. Sci. doi: 10.1002/jps.20906 contributor: fullname: Guzman – volume: 99 start-page: 1254 year: 2010 ident: 10.1016/j.ijpharm.2018.02.013_b0090 article-title: Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis publication-title: J. Pharm. Sci. doi: 10.1002/jps.21903 contributor: fullname: Murdande – volume: 415 start-page: 89 year: 2011 ident: 10.1016/j.ijpharm.2018.02.013_b0030 article-title: Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2011.05.055 contributor: fullname: Han – volume: 3 start-page: 130 year: 2010 ident: 10.1016/j.ijpharm.2018.02.013_b0005 article-title: Preparation and evaluation of solid dispersion of terbinafine hydrochloride publication-title: Int. J. Pharm. Sci. Rev. Res. contributor: fullname: Arunprasad – volume: 54 start-page: 107 year: 2002 ident: 10.1016/j.ijpharm.2018.02.013_b0010 article-title: Melt extrusion: from process to drug delivery technology publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/S0939-6411(02)00061-9 contributor: fullname: Breitenbach – volume: 286 start-page: 538 year: 2015 ident: 10.1016/j.ijpharm.2018.02.013_b9000 article-title: Pharmacological and histological examination of atorvastatin-PVP K30 solid dispersions publication-title: Powder Technol. doi: 10.1016/j.powtec.2015.08.047 contributor: fullname: Jahangiri – volume: 267 start-page: 79 year: 2003 ident: 10.1016/j.ijpharm.2018.02.013_b0150 article-title: Establishment of new preparation method for solid dispersion formulation of tacrolimus publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2003.07.010 contributor: fullname: Yamashita – volume: 1 start-page: 386 year: 2008 ident: 10.1016/j.ijpharm.2018.02.013_b0015 article-title: Preparation and characterization of solid dispersion tablet of furosemide with crospovidone publication-title: J. Pharm. Tech. contributor: fullname: Chaulang – start-page: 727 year: 2011 ident: 10.1016/j.ijpharm.2018.02.013_b0120 article-title: Improvement of the dissolution rate of poorly soluble drugs by solid crystal suspensions publication-title: Mol. Pharm. doi: 10.1021/mp1003493 contributor: fullname: Thommes – volume: 301 start-page: 199 year: 2005 ident: 10.1016/j.ijpharm.2018.02.013_b0140 article-title: Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2005.05.017 contributor: fullname: Won – volume: 12 start-page: 1203 year: 2015 ident: 10.1016/j.ijpharm.2018.02.013_b0110 article-title: Evolution of supersaturation of amorphous pharmaceuticals: Nonlinear rate of supersaturation generation regulated by matrix diffusion publication-title: Mol. Pharm. doi: 10.1021/mp500711c contributor: fullname: Sun – volume: 50 start-page: 47 year: 2000 ident: 10.1016/j.ijpharm.2018.02.013_b0065 article-title: Improving drug solubility for oral delivery using solid dispersions publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/S0939-6411(00)00076-X contributor: fullname: Leuner – volume: 85 start-page: 799 year: 2013 ident: 10.1016/j.ijpharm.2018.02.013_b0130 article-title: Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2013.09.007 contributor: fullname: Vo – volume: 7 start-page: 1 year: 2006 ident: 10.1016/j.ijpharm.2018.02.013_b0085 article-title: Enhancement of dissolution profile by solid dispersion (kneading) technique publication-title: AAPS PharmSciTech doi: 10.1208/pt070368 contributor: fullname: Modi – volume: 60 start-page: 459 year: 2012 ident: 10.1016/j.ijpharm.2018.02.013_b0100 article-title: Polymer combination increased both physical stability and oral absorption of solid dispersions containing a low glass transition temperature drug : physicochemical characterization and in vivo study publication-title: Chem. Pharm. Bull. doi: 10.1248/cpb.60.459 contributor: fullname: Sakurai – volume: 88 start-page: 1058 year: 1999 ident: 10.1016/j.ijpharm.2018.02.013_b0105 article-title: Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs publication-title: J. Pharm. Sci. doi: 10.1021/js980403l contributor: fullname: Serajuddln – volume: 44 start-page: 235 year: 2000 ident: 10.1016/j.ijpharm.2018.02.013_b0080 article-title: Drug-like properties and the causes of poor solubility and poor permeability publication-title: J. Pharamacol. Toxicol. Methods doi: 10.1016/S1056-8719(00)00107-6 contributor: fullname: Lipinski – volume: 159 start-page: 85 year: 1997 ident: 10.1016/j.ijpharm.2018.02.013_b0095 article-title: Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose publication-title: Int. J. Pharm. doi: 10.1016/S0378-5173(97)00274-3 contributor: fullname: Okimoto – volume: 9 start-page: e79 year: 2012 ident: 10.1016/j.ijpharm.2018.02.013_b0125 article-title: The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate publication-title: Drug Discov. Today Technol. doi: 10.1016/j.ddtec.2011.10.002 contributor: fullname: Van Den Mooter – volume: 109 start-page: 14 year: 2016 ident: 10.1016/j.ijpharm.2018.02.013_b0135 article-title: Physicochemical properties of direct compression tablets with spray dried and ball milled solid dispersions of tadalafil in PVP-VA publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2016.09.011 contributor: fullname: Wlodarski – volume: 52 start-page: 244 year: 2004 ident: 10.1016/j.ijpharm.2018.02.013_b0040 article-title: Application of nilvadipine solid dispersion to tablet formulation and manufacturing using crospovidone and methylcellulose as dispersion carriers publication-title: Chem. Pharm. Bull. doi: 10.1248/cpb.52.244 contributor: fullname: Hirasawa – volume: 12 start-page: 120 year: 2015 ident: 10.1016/j.ijpharm.2018.02.013_b0050 article-title: Eff ect of tablet structure on controlled release from supersaturating solid dispersions containing glyceryl behenate publication-title: Mol. Pharm. doi: 10.1021/mp500480y contributor: fullname: Keen – volume: 445 start-page: 108 year: 2013 ident: 10.1016/j.ijpharm.2018.02.013_b0055 article-title: Supersaturatable formulations for the enhanced oral absorption of sirolimus publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2013.01.067 contributor: fullname: Kim – volume: 17 start-page: 285 year: 2012 ident: 10.1016/j.ijpharm.2018.02.013_b0060 article-title: A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept publication-title: Pharm. Dev. Technol. doi: 10.3109/10837450.2010.535826 contributor: fullname: Ku – volume: 420 start-page: 1 year: 2011 ident: 10.1016/j.ijpharm.2018.02.013_b0045 article-title: Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system : Basic approaches and practical applications publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2011.08.032 contributor: fullname: Kawabata – volume: 3 start-page: 926 year: 2004 ident: 10.1016/j.ijpharm.2018.02.013_b0020 article-title: Drugs as materials: valuing physical form in drug discovery publication-title: Nat. Rev. contributor: fullname: Gardner – volume: 5 start-page: 82 year: 2002 ident: 10.1016/j.ijpharm.2018.02.013_b0075 article-title: Poor aqueous solubility – an industry wide problem in drug discovery publication-title: Am. Pharm. Rev. contributor: fullname: Lipinski |
SSID | ssj0006213 |
Score | 2.3929706 |
Snippet | [Display omitted]
The effects of tablet preparation and subsequent film coating with amorphous solid dispersion (ASD) particles that were composed of a drug... The effects of tablet preparation and subsequent film coating with amorphous solid dispersion (ASD) particles that were composed of a drug with poor water... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 171 |
SubjectTerms | Amorphous solid dispersion Copovidone Dissolution model Melt extrusion Polyvinylpyrrolidone Solid–liquid interface |
Title | Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions |
URI | https://dx.doi.org/10.1016/j.ijpharm.2018.02.013 https://www.ncbi.nlm.nih.gov/pubmed/29447848 https://search.proquest.com/docview/2003037365 |
Volume | 540 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA6iFy_i2_VFBPFkd9tNm7bHZVFWRRFU8BaySQpd3LbYevDixT_uTJq6eBDBY5u0TTPTmS_NzDeEnPq-4YqlzEvBv3oIeL1UZdrLwPdoWDZnxtI13d7xyVN4_Rw9L5FxlwuDYZXO9rc23Vprd2bgZnNQ5fngwWe2sDwqJcbHoR0Owf2BTvc_FmEefOhKJMNqCXsvsngGs34-q5AgGiO8EkvdGbDf_NNv-NP6oct1suYAJB21Y9wgS6bYJGf3LQP1-zl9XCRU1ef0jN4vuKnft8hny1Zc0zKjDWZNNRRRq6vhRWWhaQ2mxMZXQ1P-MqeqlBgaTaEZwCI0V4AYkQ4UUKqmuJ_vtJd2Kf94czkvQYLlW02hObf9qvbXXL1Nni4vHscTz9Vh8BTjUeMh6V4mdaBlAtPJUj_VkQmYAiTFuOGwglNTWNZlYexPs2FslI59FXATxZJFjEu2Q5aLsjB7hMaB1gnXKvDhqkDyhHGsYGmYlCYKplGP9LvZF1VLtyG6OLSZcOISKC7hDwWIq0eSTkbih94IcAl_XXrSyVTAN4UbJbIwMDFYmhM8ewwv3yO7rbC_RzNMwzBOwmT__w8-IKt4ZON_okOy3Ly-mSOANs302OruMVkZXd1M7r4AHFX7Gg |
link.rule.ids | 315,783,787,4509,24128,27936,27937,45597,45691 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwELYqOMAF8abLY42EOJE2qRMnOaJqUZeXkCgSN8u1HSkVTaJNOHDhwh9nxnG24oBW2mvGSRzPZOZzMvMNIWe-b7hiKfNSiK8eAl4vVZn2Mog9GrbNmbF0TXf3fPIUXj9Hzz0y7mphMK3S-f7Wp1tv7Y4M3WoOqzwfPvrMNpZHo8T8OPDDqyHiYzDqwfsyz4OPXI9k2C7h8GUZz3A-yOcVMkRjildiuTsD9l2A-g6A2kB0tUk2HIKkl-0kt0jPFNvk_KGloH67oNNlRVV9Qc_pw5Kc-m2HfLR0xTUtM9pg2VRDEba6Jl5UFprW4EtsgjWI8pcFVaXE3GgKYkCLIK4AMiIfKMBUTfGHvjNf2tX848XlogQVlq81BXFux1Xtt7l6lzxd_ZqOJ55rxOApxqPGQ9a9TOpAywSWk6V-qiMTMAVQinHDYQunZrCvy8LYn2Wj2Cgd-yrgJoolixiXbI-sFGVhDgiNA60TrlXgw1mB5Anj2MLSMClNFMyiPhl0qy-qlm9DdIloc-HUJVBdwh8JUFefJJ2OxBfDERAT_nXqaadTAS8V_imRhYGFwd6cENpjePg-2W-V_Xc2ozQM4yRMfvz_jX-Stcn07lbc_r6_OSTrKLHJQNERWWn-vJpjwDnN7MTa8Sfs_vyz |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+tablet+formulation+and+subsequent+film+coating+on+the+supersaturated+dissolution+behavior+of+amorphous+solid+dispersions&rft.jtitle=International+journal+of+pharmaceutics&rft.au=Sakai%2C+Toshiro&rft.au=Hirai%2C+Daiki&rft.au=Kimura%2C+Shin-Ichiro&rft.au=Iwao%2C+Yasunori&rft.date=2018-04-05&rft.eissn=1873-3476&rft.volume=540&rft.issue=1-2&rft.spage=171&rft_id=info:doi/10.1016%2Fj.ijpharm.2018.02.013&rft_id=info%3Apmid%2F29447848&rft.externalDocID=29447848 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-5173&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-5173&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-5173&client=summon |